semaglutide mash approval Resmetirom and GLP-1 agonists for MASH: complementary rather than exclusive semaglutide fda approval mash (Wegovy)

While this modest weight loss can provide health benefits, it is substantially less than what is achieved with prescription semaglutide

sub-label activity

Nat Rev Dis Prim

Mehmet Oz, CMS Administrator, described GLP-1 therapies as a major medical advancement that too many seniors cannot currently access due to cost constraints

In the same announcement, Coherus reported that in the process of inspecting three sites in China enrolling patients for two pivotal trials of its PD-1 antibody toripalimab in recurrent nasopharyngeal carcinoma (NPC), the FDA identified one observation

This indicates that the drug solution homogeneously permeates through gaps of the tissue having a mesh network (Fig